CommentaryINSIDER VIEWS

What Is the Greatest Regulatory Challenge in the Translation of Biomaterials to the Clinic?

  1. Glenn D. Prestwich1,*,
  2. Sangeeta Bhatia2,
  3. Christopher K. Breuer3,
  4. Shannon L. M. Dahl4,
  5. Chris Mason5,
  6. Richard McFarland6,
  7. David J. McQuillan4,
  8. Jonathan Sackner-Bernstein7,
  9. Jeffrey Schox8,
  10. William E. Tente4 and
  11. Alan Trounson9
  1. 1Department of Medicine, University of Utah, Salt Lake City, UT 84108, USA.
  2. 2Koch Institute for Integrative Cancer Research and Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
  3. 3Center for Regenerative Medicine and Cell-Based Therapies, Wexner Medical Center, Nationwide Children’s Hospital, Ohio State University, Columbus, OH 43205, USA.
  4. 4Humacyte, 7020 Kit Creek Road, Suite 110, Research Triangle Park, NC 27709, USA.
  5. 5Advanced Centre for Biochemical Engineering, University College London, London WC1E 6BT, UK.
  6. 6Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Rockville, MD 20852, USA.
  7. 7Neostem, New York, NY 10170, USA.
  8. 8Schox PLC, San Francisco, CA 94107, USA.
  9. 9California Institute for Regenerative Medicine, San Francisco, CA 94107, USA.
  1. ↵*Corresponding author. E-mail: glenn.prestwich{at}pharm.utah.edu
Science Translational Medicine  14 Nov 2012:
Vol. 4, Issue 160, pp. 160cm14
DOI: 10.1126/scitranslmed.3004915

You are currently viewing the abstract.

View Full Text

Via AAAS ID

Via your Institution

Log in through your institution

Log in through your institution

Free with registration

Abstract

Leaders in the field comment on what they perceive to be the greatest barriers to biomaterial translation.

View Full Text

Article Tools

  • Email
  • Download Powerpoint
  • Print
  • Save to my folders
  • Alerts
  • Request Permissions
  • Citation tools

  • What Is the Greatest Regulatory Challenge in the Translation of Biomaterials to the Clinic?

    By Glenn D. Prestwich, Sangeeta Bhatia, Christopher K. Breuer, Shannon L. M. Dahl, Chris Mason, Richard McFarland, David J. McQuillan, Jonathan Sackner-Bernstein, Jeffrey Schox, William E. Tente, Alan Trounson

    Science Translational Medicine : 160cm14

    Leaders in the field comment on what they perceive to be the greatest barriers to biomaterial translation.

    Permalink: Copy
    CiteULike logo Connotea logo del.icio.us logo Digg logo Facebook logo Google logo Mendeley logo Reddit logo Twitter logo

Related Content

Similar Articles in:

Cited By...

Citing Articles in: